These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Schwarz J; Tatsch K; Arnold G; Ott M; Trenkwalder C; Kirsch CM; Oertel WH Neurology; 1993 Dec; 43(12 Suppl 6):S17-20. PubMed ID: 8264906 [TBL] [Abstract][Full Text] [Related]
11. IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. Tissingh G; Booij J; Winogrodzka A; van Royen EA; Wolters EC J Neural Transm Suppl; 1997; 50():31-7. PubMed ID: 9120422 [TBL] [Abstract][Full Text] [Related]
12. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197 [TBL] [Abstract][Full Text] [Related]
13. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Seeman P; Tallerico T Am J Psychiatry; 1999 Jun; 156(6):876-84. PubMed ID: 10360126 [TBL] [Abstract][Full Text] [Related]
14. Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Kugaya A; Fujita M; Innis RB Ann Nucl Med; 2000 Feb; 14(1):1-9. PubMed ID: 10770574 [TBL] [Abstract][Full Text] [Related]
15. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409 [TBL] [Abstract][Full Text] [Related]
16. Multivariate cluster analysis of dynamic iodine-123 iodobenzamide SPET dopamine D2 receptor images in schizophrenia. Acton PD; Pilowsky LS; Costa DC; Ell PJ Eur J Nucl Med; 1997 Feb; 24(2):111-8. PubMed ID: 9021106 [TBL] [Abstract][Full Text] [Related]
17. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders]. Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375 [TBL] [Abstract][Full Text] [Related]
18. Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. Nadeau SE; Couch MW; Devane CL; Shukla SS J Nucl Med; 1995 Mar; 36(3):384-93. PubMed ID: 7884499 [TBL] [Abstract][Full Text] [Related]
19. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102 [TBL] [Abstract][Full Text] [Related]
20. [123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Schwarz J; Tatsch K; Gasser T; Arnold G; Oertel WH Mov Disord; 1997 Nov; 12(6):898-902. PubMed ID: 9399212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]